Phathom Pharmaceuticals, Inc. (PHAT) |
| 5.67 -1.34 (-19.12%) 10-23 10:28 |
| Open: | 6.72 |
| High: | 6.76 |
| Low: | 5.58 |
| Volume: | 781,123 |
| Market Cap: | 459(M) |
| PE Ratio: | -4.43 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.84 |
| Resistance 1: | 6.98 |
| Pivot price: | 6.99 |
| Support 1: | 5.58 |
| Support 2: | 4.64 |
| 52w High: | 18.31 |
| 52w Low: | 5.58 |
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Financials
| EPS | -1.260 |
| Book Value | -4.300 |
| PEG Ratio | 0.00 |
| Gross Profit | 2.456 |
| Profit Margin (%) | -41.34 |
| Operating Margin (%) | -5.34 |
| Return on Assets (ttm) | -8.8 |
| Return on Equity (ttm) | 0.0 |
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
